DFTX as reported
Definium Therapeutics, Inc. reported $4.7M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$4.7M
Revenue, trailing twelve months · to Q4 2023 · every figure below is as filed, with no scoring applied
- Net Income
- −$354M
Net Income · +209% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.43
EPS · +123% year on year · trailing twelve months to Q2 2026
- ROIC
- 269%
ROIC · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $4.7M | n/a | Q4 2023 · 10 quarters behind |
| Net Income | −$354M | +209% | Q2 2026 |
| EPS | −$3.43 | +123% | Q2 2026 |
| Op Margin | −2041% | n/a | Q4 2023 · 10 quarters behind |
| Net Margin | −2083% | n/a | Q4 2023 · 10 quarters behind |
| ROE | −77% | n/a | Q2 2026 |
| ROA | −51% | n/a | Q2 2026 |
| ROIC | 269% | n/a | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Definium Therapeutics, Inc. (DFTX) - Revenue & ProfitRevenue & ProfitDefinium Therapeutics, Inc. (DFTX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com